Skip to main content
SpringerLink
Log in

Patients’ health or company profits? The commercialisation of academic research

  • Published:
Science and Engineering Ethics Aims and scope Submit manuscript

Abstract

This paper is a personal account of the events associated with the author’s work at the University of Toronto’s Hospital for Sick Children on a drug, deferiprone, for the treatment of thalassaemia. Trials of the drug were sponsored by the Canadian Medical Research Council and a drug company which would have been able, had the trials been successful, to seek regulatory approval to market the drug. When evidence emerged that deferiprone might be inadequately effective in a substantial proportion of patients, the drug company issued legal threats when the author proposed informing her patients and the scientific community. Until protests were made by international authorities in her field of research, the hospital and university did not adequately support the author’s academic freedom and responsibilities as a medical practitioner.

It is argued that underlying cause of this, and of other similar cases, is the political philosophy which is driving the commercialisation of universities and bringing about the deregulation of drug approval procedures. Together these changes constitute a serious threat to the public good.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thompson, J., Baird, P. and J. Downie, J. (October 2001) The Olivieri Report, The complete text of the independent inquiry commissioned by the Canadian Association of University Teachers, James Lorimer and Company, Toronto.

    Google Scholar 

  2. Thompson, J., Baird, P. and Downie, J. (2002) Supplement to the Report of the Committee of Inquiry on the Case Involving Dr. Nancy Olivieri, he Hospital for Sick Children, the University of Toronto, and Apotex Inc. 30th Jan. (http://www.caut.ca/english/publications/news_releases/20020131_olivieri.asp Accessed 22.10.02)

  3. di Norcia, V. (2003) The Olivieri Report-A Compelling Study of the Growing Tensions in Clinical Research, Science & Engineering Ethics 9: 125–132.

    Google Scholar 

  4. Weatherall D.J. and Clegg, J.B. (August 1996) Thalassemia — A global public health problem Nat. Med. 2 (8): 847–849.

    Article  Google Scholar 

  5. Olivieri, N.F., Brittenham, G.M., Matsui, D., Berkovitch, M., Blendis, L.M., Cameron, R.G., Mcclelland, R.A., Liu, P.P., Templeton, D.M. and Koren, G. (1995) Iron-chelation therapy with oral deferiprone in patients with thalassemia major N. Engl. J. Med. 332(14): 918–922.

    Article  Google Scholar 

  6. Somerville, M.A. (2002) Nature Reviews, Drug Discovery 1, 316.

    Article  Google Scholar 

  7. Olivieri, N. (1999) HSC clinical trials controversy continues, Nature Medicine 5(1): 3.

    Article  Google Scholar 

  8. Bonetta, L. (2000) Hate-mail author trapped by DNA, Nature Med. 6(4): 364.

    Google Scholar 

  9. Birmingham, K. (2000) Second HSC researcher sends anonymous ‘Olivieri’ note, Nature Med. 6: 485.

    Google Scholar 

  10. Birmingham, K. (2000) No dismissal for hate-mail author, Nature Medicine, 6(6): 609–610.

    Article  Google Scholar 

  11. Bonetta, L. (2001) Olivieri to testify against Apotex in Europe, Nature Medicine 7(6), 644.

    Article  Google Scholar 

  12. Roush, W. (1997) Science and Commerce: Secrecy Dispute Pits Brown Researcher Against Company. Science 276: 523.

    Article  Google Scholar 

  13. Marcus, J. (1999) How researchers are silenced by ‘pact with devil’, Times Higher Education Supplement, 11 June.

  14. CAUT Bulletin, June 1999 http://www.caut.ca/English/Bulletin/99_jun/brown.htm (accessed 24.x.02).

  15. Shuchman, M. (1998) Secrecy in Science: The Flock Worker’s Lung Investigation, Annals of Internal Medicine 15 August, pp. 341–344.

    Google Scholar 

  16. Kern, D.G., Kern, R.K. and Durand, K.T.H. (1999) Annals of Internal Medicine 130(7): 616.

    Google Scholar 

  17. Kern, D.G., Crausman, R.S., Durand, K.T.H. et al. (1998) Flock worker’s lung: Chronic interstitial lung disease in the nylon flocking industry Annals of Internal Medicine 129(4): 261.

    Google Scholar 

  18. Zinberg, D.S. (1996) Editorial: A Cautionary Tale, Science 273: 411.

    Article  Google Scholar 

  19. McCarthy, M. (1997) News-Sponsors lose fight to stop thyroxine study publication, Lancet 349: 1149(1997).

    Article  Google Scholar 

  20. Vogel, G. (1997) Long Suppressed Study Finally Sees Light of Day, Science 276: 523–525.

    Article  Google Scholar 

  21. Evans, G.R. (1999) Calling Academia to Account, SRHE & Open University Press.

  22. Dong, B.J., Hauck, W.W., Gambertoglio, J.G., Gee, L., White, J.R., Bubp, J.L. and Greenspan, F.S. (1997) Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism, J. Am. Med. Assoc. 277(15): 1205.

    Article  Google Scholar 

  23. Rennie, D. (1997) Thyroid Storm, Jama 277(15): 1238–43.

    Article  Google Scholar 

  24. Packham, D, Impact of Commercialisation and Privatisation on Capabilities for Scientific Advice in Oracles or Scapegoats? Scientists and scientific advice in government policy making, Report of the conference on 28th Oct. 1999, Westminster Conference Centre, I.P.M.S, p. 11.

  25. http://acst-ccst.gc.ca/comm/home_e.html. Accessed 24.10.02.

  26. Ziman, J. (2003) Non-instrumental roles of science, Science and Engineering Ethics 9: 17–27.

    Google Scholar 

  27. Tasker, M. & Packham, D. (1994) Government, Higher Education and the Industrial Ethic, Higher Education Quarterly 48(3): 182.

    Google Scholar 

  28. Tasker, M. & Packham, D. (1993) Industry and Higher Education: a Question of Values, Studies in Higher Education, 18: 127.

    Article  Google Scholar 

  29. McMurtry, J. (1991) Education and the Market Model, Journal of Philosophy of Education 25: 209.

    Article  Google Scholar 

  30. Angell, M. (2000) The Pharmaceutical Industry — To Whom Is It Accountable? New England Journal of Medicine 342 (25): 1902–1904.

    Article  Google Scholar 

  31. Angell, M., Urtiger, R.D. and Wood, A.J.J. (2000) New England Journal of Medicine, 342: 586.

    Article  Google Scholar 

  32. Krimsky, S., Rothenberg, L.S., Stott, P. and Kyle, G. (1996) Financial Interests of Authors in Scientific Journals: A Pilot Study of 14 Publications, Scence and. Engineering. Ethics 2(4): 395–410.

    Article  Google Scholar 

  33. Weatherall, D. (2003) Science, Problems for biomedical research at the academia-industrial interface, Scence and. Engineering Ethics 9: 43–48.

    Google Scholar 

  34. Davidoff, F. et al. (2001) Sponsorship, authorship and accountability, The Lancet, 358: 854.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Toronto, University Health Network, Toronto General Hospital, 101, College Street, College Wing, 3rd Floor, Room # CW3-338, M5G 2C4, Toronto, ON, Canada

    Nancy F. Olivieri MD (Professor, Pediatrics and Medicine)

Authors
  1. Nancy F. Olivieri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy F. Olivieri MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olivieri, N.F. Patients’ health or company profits? The commercialisation of academic research. SCI ENG ETHICS 9, 29–41 (2003). https://doi.org/10.1007/s11948-003-0017-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11948-003-0017-x

Keywords

Search

Navigation